Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a recently described member of the epidermal growth factor (EGF) family. It binds to heparan sulfate proteoglycans via a cationic domain and is a potent mitogen for epithelial cells, fibroblasts and vascular smooth muscle cells. In the present study we have attempted to identify changes in quantity and distribution of HB-EGF in two models of acute glomerular epithelial cell injury, using Western blotting, immunohistochemistry and in situ hybridization. Prior to disease induction, Western blots showed some expression of HB-EGF protein within glomeruli. Within the first three days in the acute puromycin aminonucleoside (PAN) and passive Heymann nephritis (PHN) models, immunohistochemistry and in situ hybridization demonstrated an up-regulation of HB-EGF mRNA and protein in glomerular epithelial cells (GEC). In both cases, increased protein and mRNA was found prior to the onset of proteinuria and continued until day 21 post-induction, the last time point studied. Early in the course of the models, HB-EGF was localized to the cytoplasm of glomerular epithelial cells. At day 21, however, HB-EGF protein was distributed in a nodular pattern within GEC and along the glomerular basement membrane (GBM) in both models, suggesting that the secreted form might bind to the membrane. The increase in HB-EGF protein within glomeruli was confirmed by Western blots of glomerular membrane protein which, however, demonstrated a single 29 kDa species, consistent with the transmembrane form. These data are not consistent with binding of the secreted form of HB-EGF to the GBM. The transmembrane form of HB-EGF is able to signal in a juxtracrine fashion, so increased expression of HB-EGF mRNA and protein by GEC might contribute to the genesis of proteinuria through the initiation of abortive GEC mitogenesis.
Several growth factors have been described that bind heparan sulfate proteoglycans using cationic domains within their amino acid sequences. Among these are fibroblast growth factors-1 and -2 (FGF-1 and FGF-2) [1] , platelet-derived growth factor (PDGF) [2] , and heparin-binding epidermal growth factor-like growth factor (HB-EGF) [3] [4] [5] . As with other members of the epidermal growth factor family, HB-EGF is synthesized as a transmembrane precursor ( Fig. 1A) that is cleaved by an unknown protease to yield the mature protein of 75 to 86 amino acids [6] . The heparin-binding domain is cationic and predominantly contained within an N-terminal hydrophilic region in the mature peptide ( Fig. 1B) that is linked to the C-terminal EGF-like domain [4, 7] .
Although it has long been known that the glomerular basement membrane (GBM) is rich in anionic heparan sulfate proteoglycans (HSPG) [8 -12] , there has been little interest in the possibility that heparin-binding growth factors could bind to the GBM and alter its function. Heparin-binding growth factors could interfere with glomerular filtration and lead to proteinuria through the neutralization of negative charge (although the importance of charge as a barrier to filtration of macromolecules has recently been questioned [13] ), or alteration of the tertiary structure of the GBM. Moreover, abortive mitogenesis of glomerular epithelial cells (GEC) has recently been proposed as a mechanism for loss of these cells from the surface of the GBM [14] , and bare areas of the GBM have long been known to leak plasma proteins [15, 16] . Since some of these growth factors, including HB-EGF, are potent epithelial cell mitogens they might stimulate abortive mitogenesis, thus causing loss of GEC from the GBM, and proteinuria.
In an earlier study, we reported that HB-EGF mRNA was up-regulated in visceral glomerular epithelial cells in the Thy 1.1 model of mesangial proliferative glomerulonephritis [17] [18] [19] . This was a surprising finding, because the glomerular mesangial cell synthesizes HB-EGF following various activating stimuli in vitro [17] [18] [19] and is the primary target of injury in this model. In view of this unexpected finding in the Thy 1.1 model, we have attempted to detect HB-EGF mRNA and protein in the acute puromycin aminonucleoside (PAN) and acute passive Heymann nephritis (PHN) models of human minimal change disease and membranous glomerulonephritis, respectively. Both are due to primary GEC injury and produce significant proteinuria. of sheep with a rat Fx1A preparation. 1 ml of Fx1A (20 mg/ml) was mixed with an equal volume of complete Freund's adjuvant (Sigma Chemical Co., St. Louis, MO, USA) for the first immunization and incomplete Freund's adjuvant for all subsequent immunizations. Immunizations were administered at monthly intervals for a total of six months. Activity of the antiserum was assayed by immunodiffusion in agar against Fx1A and by immunohistochemical staining of rat kidney. The antiserum produced precipitin lines against Fx1A at dilutions of Ͼ 1/64 and stained tubules in rat kidney at dilutions up to 1/10,000. The sheep antiserum was then heat inactivated, precipitated with 40% ammonium sulphate, absorbed with rat erythrocytes and rat serum coupled to Sepharose, dialyzed against 400 volumes of PBS, and concentrated to 20 mg/ml. 0.6 ml of anti-Fx1A (20 mg/ml) was administered by intravenous injection on two consecutive days to 150 to 200 g male Sprague-Dawley rats following dose finding studies and using a protocol supplied by Dr. David Salant. Animals were fed on chow and water ad libitum. Urine was collected in metabolic cages and urinary protein determined using a modified Lowry assay (BioRad, Hercules, CA, USA). Proteinuria was detected five days after the first injection (108 Ϯ 68 mg/24 hr) and the presence of electron dense deposits confirmed by electron microscopy. Activity of the antiserum was compared with that of a known anti-Fx1A antiserum that was a gift of Dr. Salant. Rats were sacrificed at days 0, 1, 3, 5, 7, 10, 14, 17, and 21 after induction using intraperitoneal pentobarbital 50 mg/kg to induce anesthesia. In the intial studies, each group comprised three rats, but this was subsequently increased to six per group.
Acute puromycin aminonucleoside nephrosis (PAN). Acute puromycin aminonucleoside nephrosis was induced in 150 to 200 g Sprague-Dawley rats using an established protocol by a single intravenous injection of 15 mg/100 g puromycin aminonucleoside (Sigma) [15] . Proteinuria at day 5 post-injection was 284 Ϯ 113 mg/24 hr. Rats were sacrificed in groups of three at days 0, 1, 2, 3, 5, 7, 14, and 21. At least six rats were used per group.
Experimental design
Rats with PHN or PAN were sacrificed and both kidneys removed. Biopsies were obtained for three fixation conditions: (1) 4% paraformaldehyde, (2) 2% glutaraldehyde, and (3) snap frozen in OCT. The rest of the renal tissue (generally one whole kidney from each rat) was then used to isolate glomeruli by differential sieving [21] . Biopsies obtained from three to six rats at each time point were used for immunohistochemical staining and in situ hybridization.
Preparation of rabbit anti-HB-EGF polyclonal antibodies
Rabbit anti-HB-EGF antibodies were produced using two immunizing antigens. Firstly, four New Zealand white rabbits were immunized subcutaneously with recombinant human HB-EGF (R&D Systems, Minneapolis, MN, USA), using 5 g per immunization mixed with complete Freund's adjuvant on the first occasion, and incomplete Freund's adjuvant on a further three occasions at four weekly intervals. Following ELISA and immunohistochemical assays of multiple test bleeds, serum from one of the animals (R847) was incubated at 56°C for 45 minutes to inactivate complement, diluted in PBS, and affinity purified on a Protein G Sepharose column (Sigma). The resultant antibody was concentrated to 1 mg/ml in PBS with Na azide. Secondly, a 24 amino acid peptide sequence, comprising residues 69-92 of rat HB-EGF (rHB-EGF 69-92 ; LDLFKVAFSSKPQALATPGKEKNG) [22] was synthesized and coupled to keyhole limpet hemocyanin (KLH) and, separately, ovalbumin (OVA) via a C-terminal GGC tag by Dr. John Fecondo at Swinburne University, Victoria, Australia. Four New Zealand White rabbits were immunized on one occasion with 5 g of KLH-coupled peptide in complete Freund's adjuvant, followed by three further immunizations of peptide coupled to OVA in incomplete Freund's adjuvant at monthly intervals, following a protocol described by van Adelsberg and Frank [23] . Following ELISA and immunohistochemical assays of multiple test bleeds, serum from one of the animals (R866) was incubated at 56°C for 45 minutes to inactivate complement and used as a diluted antiserum in further studies.
Antibody characterization using Western blotting
Serum from the four rabbits in the two immunization groups was assayed repeatedly against normal rat kidney sections and sections from rats with passive Heymann nephritis. Only one in each group showed any immunohistochemical reactivity (R847 and R866), and these were the only sera to show reactivity against the immunizing antigen in ELISA. The specificity of both antibodies was confirmed by Western blotting, using rat kidney and mesangial cell lysates, and recombinant human HB-EGF blotted onto nitrocellulose membranes. Briefly, cytoplasmic fractions of rat kidney or confluent rat mesangial cells were used. Mesangial cells were lysed in reducing SDS-PAGE sample buffer. Rat kidneys were homogenized in 3 ml homogenization buffer (50 mM Tris-HCl pH 8.5, 250 mM sucrose, 5 mM pyrophosphate, 50 mM sodium fluoride, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 1 mM benzamidine, 0.2 mM phenylmethylsulfonylfluoride) with a glass/ Alignment of the mature forms (that is, after cleavage of the transmembrane form) of the five members of the EGF family with the N-terminal end of EGF (human sequences). The heparin-binding domain of HB-EGF (underlined), which is rich in the basic amino acid residues, arginine (R) and lysine (K), is seen to extend into the EGF-like domain and to include the first conserved cysteine (C) residue. The first two of the six conserved cysteine residues are shown in bold. HB-EGF and AR are strongly heparin-binding, BTC is a very weak binder, and EGF and TGF-␣ do not bind. Single letter amino acid code. teflon homogenizer. Homogenates were centrifuged (14,000 rpm, 5 min, 4°C) in a microcentrifuge to remove nuclei and the superntatant centrifuged in an ultracentrifuge (50,000 rpm, 60 min, 4°C) to remove cell membranes. Protein concentrations were determined using the Lowry method. Mesangial cell lysates and rat kidney cytoplasmic fractions (boiled in SDS-PAGE sample buffer so that approximately 40 g of protein was added per well on the final gel) were run on 12.5% SDS-PAGE gels together with low molecular weight markers (Rainbow; Amersham PLC) at 160 volts/30 mAmp for two hours, using the Bo-Rad Minigel apparatus and then transferred to nitrocellulose membranes. The blots were blocked with 3% skim milk (SM) in Tris-buffered saline with 0.1% Tween (TBST) for 60 minutes. The blots were then incubated with rabbit anti-HB-EGF antibodies (R847 at 2 g/ml; R866 diluted 1:1,000) in 3% SM/TBST for 60 minutes before washing and incubation with horseradish peroxidase linked Protein A (Amersham PLC) diluted 1:500 in 3% SM/TBST for 30 minutes. The blots were then incubated with ECL reagents (Amersham PLC) and exposed on X-ray film. Normal rabbit serum or purified rabbit Ig (Sigma) were used as negative controls. For Western blots using recombinant human growth factors, EGF (Sigma), TGF-␣ (Sigma), betacellulin (R&D Systems), amphiregulin (R&D Systems), and HB-EGF (R&D Systems) were boiled in SDS-PAGE sample buffer (reducing) and 200 ng per well loaded onto each gel. The blots were then probed with R866, R847 or control antibody as outlined above.
Immunohistochemical staining
Tissue blocks were immersion fixed in 4% paraformaldehyde and embedded in paraffin. Four-micrometer thick paraffin sections were cut on a microtome and dried overnight at 37°C. A variety of incubation times, antibody dilutions, blocking solutions and enzyme treatments were tested before optimal staining was obtained. Experimental pretreatments used included microwaving, or incubation with enzymes such as pronase E, proteinase K, hyaluronidase, proteinase VIII, and proteinase XXIV (all from Sigma). The following protocol produced optimal staining and was ultimately adopted; sections were dewaxed and treated with 0.1% pronase E (Sigma) for six minutes at 37°C. Endogenous peroxidase activity was inhibited using 3% hydrogen peroxide for 10 minutes. Sections were then blocked with sheep serum (Gibco) for 30 minutes, and incubated overnight at 4°C with rabbit anti-HB-EGF antibody, either R847 at 10 g/ml or R866 diluted 1/250. Negative controls used were normal rabbit immunoglobulin (Ig; Dako Corporation, Carpinteria, CA, USA) diluted 10 g/ml or diluted normal rabbit serum. Rabbit Ig was detected using a triple layer technique, comprising monoclonal mouse anti-rabbit Ig diluted 1/50 (Dako) followed by biotinylated sheep anti-mouse Ig diluted 1/200 (Amersham, Life Sciences, Buckinghamshire, UK) and streptavidin-conjugated horseradish peroxidase (Dako) diluted 1/300, each for 30 minutes, with washing steps between incubations. Sections were developed using nickel-enhanced diaminobenzidene (Pierce, Rockford, IL, USA) and counterstained with hematoxylin. Staining obtained with cryopreserved and mercuric chloride-fixed sections was inferior to that observed in sections stained by the method outlined above.
Localization of tubular staining using tubular markers
To determine the location of tubular staining seen with anti-HB-EGF antibodies, sequential sections were stained with tubular markers [24] . The fluorescein-labeled lectin Arachis hypogea (AH; Sigma) was used to identify distal convoluted tubules (DCT) and collecting ducts while Phaseolus vulgaris erythroagglutinin (PHA-E) was used for cells of the proximal convoluted tubule (PCT). Lectin binding was identified using immunoperoxidaseconjugated anti-FITC Fab fragments (Boehringer Mannheim, Mannheim, Germany), followed by diaminobenzidine and hematoxylin as described earlier. Rabbit anti-Tamm-Horsfall protein (THP) antibody (gift of Dr. H.Y. Lan, Monash Medical Centre, Clayton, Victoria, Australia) was used to identify cortical and medullary thick ascending limbs of the loop of Henle (TAL). The staining method used was identical to that for HB-EGF. 
In situ hybridization
A rat HB-EGF cDNA probe corresponding to positions 231-254 and 707-726, respectively, in the published sequence of rat cDNA [22] , was produced by polymerase chain reaction (PCR) amplification, as previously described [17] . Primers were selected to include the sequence encoding the mature HB-EGF protein. This 495 bp cDNA fragment was subcloned into the multiple cloning site of the plasmid pGEM-T (Promega, Madison, USA) between the SP6 and T7 promoters. The insert was sequenced over its full length on both strands and found to be identical to the published sequence of rat HB-EGF.
pGEM-T containing the HB-EGF cDNA fragment was linearized with the restriction enzymes SacII (sense probe) or Spe I (anti-sense probe). Labeled riboprobes were synthesized using T7 RNA polymerase (anti-sense probe) or SP6 RNA polymerase (sense probe) incorporating digoxigenin-labeled uridine-triphosphate (Boehringer Mannheim). The anti-sense riboprobe but not the sense riboprobe detected a 2.5 kb transcript on a Northern blot of mesangial cell RNA. Paraffin sections were cut 4 M thick. Sections were dewaxed and dehydrated in alcohol, treated with 0.2 M HCl for 20 minutes, rinsed with DEPC water ϫ2 for five minutes then placed in 2 ϫ SSC 70°C for 10 minutes and rinsed in DEPC water. Digestion of sections was undertaken with 20 g/ml proteinase K (Sigma) in 100 mM Tris-HCl pH 8.0/50 mM EDTA at 37°C for 30 minutes. Digestion was stopped by immersion in 2 mg/ml glycine in PBS. Slides were rinsed in PBS ϫ2 and fixed in 4% paraformaldehyde for 15 minutes, rinsed with PBS and equilibrated with 100 mM triethanolamine pH 8.0. Acetic anhydride was added to block positively charged groups that might bind the probe. Sections were prehybridized in hybridization buffer [50% formamide, ϫ5 SSC, 2% block reagent (Boehringer Mannheim), 0.02% SDS, 0.1% N-lauroylsarcosine] for 60 minutes at 37°C and then hybridized overnight with denatured DIGlabeled sense and antisense riboprobe at a concentration of 150 ng/ml in a humidified chamber at 42°C. After treatment of the slides with DNase-free RNase A (5 g/ml) for 30 minutes at 37°C, colorimetric detection of mRNA following hybridization was accomplished with the non-radioactive nucleic acid detection kit (Boehringer Mannheim) following the manufacturer's instructions. Sections were counterstained with Nuclear Fast Red. Tissue obtained from each of three rats was stained and examined at each time point.
Preparation of glomerular membrane protein fractions
Glomeruli were isolated from kidneys obtained from controls and rats at days 5 and 14 for the PAN model and at days 5 and 21 for the PHN model (N ϭ 3, at each time point). Subcellular fractions were prepared as described by Egerton et al [25] with minor modifications. All steps were performed at 4°C. Briefly, glomeruli were isolated as outlined above and sonicated at 3 ϫ 10 seconds at 20% setting using a Branson sonifier (Branson Ultrasonics, USA). NaCl was restored to 150 mM using 0.11 volumes of 1.5 M NaCl and the lysate centrifuged at 700 g for seven minutes to pellet nuclei. The post-nuclear supernatant was reconstituted to 5 mM EDTA and centrifuged at 100,000 g for 60 minutes to separate the soluble fraction (cytosol) from the insoluble pellet (membranes and cytoskeleton). The pellet was then solubilized in mammalian cell lysis buffer (50 mM Tris-HCl pH 7.4; 150 mM NaCl; 5 mM EDTA; 0.5% Triton X-100) and centrifuged at 12,000 g for 15 minutes to separate the soluble supernatant (membranes) from the pellet (cytoskeleton). All samples were stored at Ϫ70°C until used. For Western blots, 5 g of protein was added to each lane of a 12.5% gel.
For detection of HB-EGF protein by Western blot, protein concentrations were determined by a commercial Bradford assay (BioRad Protein Assay). Equal quantities of protein (5 g per well) were loaded onto 12.5% SDS-PAGE gels, then blotted and probed with R847 as outlined earlier. Results were quantitated by laser densitometry using a Molecular Dynamics Computing Densitometer, Model 300A and ImageQuant Software (version 3.0).
RESULTS

mRNA transcripts detected by in situ hybridization
Sense controls were negative ( Fig. 2A) , apart from occasional nonspecific staining around the edge of the section. HB-EGF mRNA transcripts were faintly detectable by in situ hybridization in occasional tubules and visceral GEC of normal rat kidney (Fig.   2B ). In the PHN model, increased HB-EGF mRNA was detected by in situ hybridization at day 3 after the first injection of anti-Fx1A and continued until day 21 (Fig. 2 C, D) . Expression by parietal and visceral GEC was markedly increased in the PAN model at days 1 and 3 post-induction, continuing until day 21 (Fig.  2 E, F) . In both models, there was a slight but widespread increase in expression by tubular cells. There was no clear increase in expression by vascular endothelial cells or smooth muscle cells of the vascular media.
Validation of anti-HB-EGF antibodies using Western blots
To determine whether anti-HB-EGF antibodies detected rat HB-EGF, unfractionated rat whole kidney (Fig. 3A) and mesangial cell (Fig. 3B ) lysates were blotted onto nitrocellulose and probed with R847 and R866. Both antibodies detected a band of 27 to 29 kDa, consistent with the transmembrane form of HB-EGF ( Fig. 3 A, B ). In addition, R847 detected a 19 to 23 kDa species when blotted against recombinant human HB-EGF ( Fig.  3C ) but not the related growth factors amphiregulin, betacellulin, EGF, and TGF-␣. R866 did not react in Western blots with any of the human growth factors (data not shown).
Immunohistochemical staining with rabbit anti-HB-EGF antibodies
Paraformaldehyde-fixed, enzyme-treated sections were stained with negative control antibody or with one of the anti-HB-EGF antibodies, R847 or R866. Sections stained with negative control antibody showed no staining. In normal kidney, there was impressive tubular expression in the outer medulla that was localized predominantly to TAL (Fig. 4A ). In the cortex, expression occurred mainly in cortical TAL ( Fig. 4 B, C) and DCT ( Fig. 4 D,  E) . Staining occurred mainly at the basolateral surface of these cells. Epithelial cells of the transitional epithelium in the papillary area, as well as smooth muscle cells and endothelium of mediumsized arteries and arterioles were also positive. There was also weaker staining in the microvillous border of cortical PCT, and occasional visceral and parietal glomerular epithelial cells. Staining in the microvillous border of cortical PCT was not always seen and appeared more intense in some of the disease models (see below).
In the disease models, negative controls showed no staining (Fig. 5A) . Normal glomeruli were usually negative (Fig. 5B) , although occasional GEC were weakly positive in some sections. Following induction of either of the two models, there was increased staining for HB-EGF within GEC (Fig. 5 C-H) ; staining for immunoreactive HB-EGF occurred within three days in both models in visceral GEC (Fig. 5C ). Staining gradually became more intense (Fig. 5E ) until, by day 21, there was clear expression in GEC in both models with small immunoreactive "nodules" and areas of apparent linear staining, some of it forming double contours ( Fig. 5 D, F-H ). The precise location of the small "nodules" was not clear but they occurred in both PAN and PHN models. Staining with a second anti-HB-EGF antibody, R847, was very similar to that seen with R866 ( Fig. 5 G, H) , although there was greater background staining with R847. In some of the disease sections, immunoreactivity in the brush border of cortical PCT and the luminal surface of distal tubules appeared greater than in control sections (for example, Fig. 5F compared with 5B) .
Detection of HB-EGF in glomerular protein fractions by Western blot
A single species of approximately 29 kDa was detected in normal glomeruli and this increased two to three times in the models (Fig. 6 ). There was no increase in the disease models between day 5 and the later days studied, and no other species was detected. Western blots of cytoplasmic protein showed no detectable HB-EGF (data not shown).
DISCUSSION
In the PHN and PAN models of proteinuria, in situ hybridization showed up-regulated expression of HB-EGF mRNA within GEC prior to the onset of proteinuria. This continued through to day 21 in both models. Immunohistochemical staining for HB-EGF also increased during the course of both models. Within the glomerulus, staining was initially confined to the body of glomerular epithelial cells within the glomerulus and occurred within three days in both models, following the pattern of increased HB-EGF mRNA determined by in situ hybridization. There were occasional areas of apparent linear staining, even at the early time points. By days 17 to 21, however, this was markedly increased with apparent membrane staining in some areas. Some of the staining within the GEC also appeared to be nodular.
The increase in HB-EGF protein was confirmed by Western blots of membrane protein fractions from isolated glomeruli. These showed a two-to threefold increase in a 29 kDa protein, consistent with the transmembrane form of HB-EGF [26] . Lower molecular mass bands that might be consistent with the secreted form were not detected. The cell-associated form of HB-EGF is able to signal in a paracrine manner [26] and GEC have been reported to possess the EGF receptor [27] . Therefore, this finding suggests that any contribution of HB-EGF to the genesis of proteinuria is likely to be as a mitogenic factor. However, it is also possible that the secreted form of HB-EGF binds to the GBM, which might be relatively poorly solubilized compared with other membrane fractions. This issue can only be resolved by Western blots of isolated GBM preparations or immunogold electron microscopy to accurately localize the increase in HB-EGF; these studies are currently in progress.
Synthesis of the mRNA or protein for a number of extracellular matrix molecules is increased in experimental membranous nephropathy [28] . This is the second growth factor reported to be up-regulated by GEC in PHN. Floege et al [29] found that PDGF protein and mRNA was increased in visceral GEC at day 3 after induction of PHN, but declined therafter. In contrast, the present studies have shown that HB-EGF mRNA and protein become clearly increased at day 3 after induction and continue to increase until day 21, the last time point studied. Floege et al have also reported that a receptor for FGF-2 (flg) is present within the immune deposits along the epithelial side of the GBM in Heymann nephritis and that the receptor is up-regulated in GEC [30] . FGF-2 synthesis, however, was not increased in the model. In human membranous glomerulonephritis, a disease closely related to PHN, tumor necrosis factor-␣ (TNF-␣) is clearly up-regulated within GEC [31] , but this observation has not yet been made in PHN. There are no data demonstrating up-regulated heparinbinding growth factor expression by GEC in acute PAN, although alterations in interleukin 1 (IL-1) and TNF have been reported in the acute phase [32] [33] [34] , and changes in various growth factors in a model of focal glomerular sclerosis have been reported at later time points [35] .
This study also describes the distribution of immunoreactive HB-EGF in normal kidney. The staining pattern differs from that described in two other publications. Nakagawa et al [36] reported predominant expression of HB-EGF protein in the S3 segment of the proximal tubule, as well as other proximal tubular cells and arterial smooth muscle. By contrast, Sakai et al [37] found immunoreactive HB-EGF in intralobular arteries and occasional cortical collecting duct cells, but no expression in the inner or outer medullas. Both groups reported no expression of HB-EGF protein in normal glomeruli [36, 37] . In the present studies, HB-EGF protein was found in isolated glomeruli by Western blot, and mRNA transcripts by both RT-PCR and Northern blots (data not shown). Histochemical staining for HB-EGF was negative in normal glomeruli. Within tubules, prominent expression of HB-EGF protein was found in TAL in the outer medulla as well as DCT. This pattern of expression is similar to that reported by Sakai et al in kidneys subjected to ischemia-reperfusion injury [37] . The differences may be due to the use of enzymatic treatment, in the present study, to reveal "hidden" epitopes. Without prior enzymatic treatment, the staining pattern observed was similar to that reported by Sakai et al [37] in normal rat kidney (data not shown). These data suggest a much more extensive distribution of HB-EGF in normal rat kidney than has previously been suggested. The protein was also localized to the basolateral surface of tubules, suggesting that it might stimulate the EGF receptor that is also located on the basolateral surface of tubular epithelium [38] .
In summary, this study has shown that HB-EGF mRNA and protein is up-regulated by GEC in two models of heavy proteinuria. Most of the increase appeared to be in a 29 kDa species, which is compatible with the transmembrane form. These studies suggest that the increase in HB-EGF is cell-associated and that HB-EGF may, therefore, stimulate mitogenesis in a juxtacrine fashion. Further studies are required, however, to determine whether the secreted form is present along the GBM.
